Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.86 HKD | -5.30% | +18.11% | -56.78% |
Jun. 05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
Jun. 05 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.78% | 373M | |
+55.70% | 59.34B | |
+41.08% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+25.85% | 12.28B | |
+2.72% | 12.49B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- UBS Adjusts Alphamab Oncology's Price Target to HK$12.94 From HK$13.22, Keeps at Buy